Experts in Ligninolytic Enzymes

Searching for new opportunities

Evolving to your needs

“All terrain” enzymes

What We Do

EvoEnzyme commercializes evolved ligninolytic enzymes and mutant libraries of fungal peroxygenases, high-redox potential laccases, versatile peroxidases and aryl alcohol oxidases for pharmaceutical, chemical, and environmental applications.

Directed enzyme evolution is our speciality: we developed directed evolution strategies to resolve your specific problem. Want to learn more about directed evolution? Click here: (https://evoenzyme.com/technology/)

NEWS

BBI-H2020 BIZENTE Project

04/01/2020

EvoEnzyme is participating as a full partner in the 4-year project BIZENTE (H2020-BBI-JTI-2019) aimed at degrading thermoset composites.

Madri+d interviews our CEO

10/3/2020

Maria Urbano, CEO of EvoEnzyme, has been interviewed by Madri+d  https://www.madrimasd.org/notiweb/noticias/apoyo-healthstart-ha-sido-basico-preparar-las-bases-un-comienzo-firme-compania

EvoEnzyme joins Susplast

22/01/2020

EvoEnzyme joins the CSIC Susplast (Interdisciplinary Platform for Sustainable Plastics towards a Circular Economy) to implement plastics management within a circular economy http://susplast-csic.org

EVOFARMA Project: the CAM-RIS 3 grant

01/02/2020

EvoFarma, the innovative EvoEnzyme´s project, has been granted with a CAM-RIS 3 for young innovative companies from the Community of Madrid and the European Regional development.

 Invited lecture at IQAC

04/03/2020, Barcelona, Spain.

Miguel Alcalde, EvoEnzyme Founder & Advisor, gave an invited lecture in the seminar program of IQAC.

EvoEnzyme at the III Simposio de la Unidad de Excelencia Química Aplicada a Biomedicina y Medioambiente

17/01/ 2020, University of Granada, Spain.

Miguel Alcalde, EvoEnzyme Founder & Advisor, made an invited lecture introducing the Company.

EvoEnzyme 1st PATENT

10/12/2020

EvoEnzyme signs an exclusive license agreement with CSIC for the exploitation of evolved peroxygenases (WO/2017/081355 approved in Europe and United States).

EvoEnzyme in COP25

2/12/2019 Madrid

The CSIC presents at COP25 six technology-based companies to face the challenges of climate change, and EvoEnzyme was one of them!!!

More info in https://www.csic.es/es/actualidad-del-csic/el-csic-presenta-en-la-cop25-seis-empresas-de-base-tecnologica-para-afrontar-los

EvoEnzyme at TrEnCa 2019

29/11/ 2020, Benicassim, Spain.

Miguel Alcalde, EvoEnzyme Founder & Advisor, made an invited lecture introducing the Company.

EvoEnzyme, “Revelation Startup Award 2019”

26/09/2019
During “III Inspiring Women Leaders in the digital Era” event in Repsol in Madrid, Women StartupCommunity awarded to EvoEnzyme as the Revelation Startup of 2019.
For further information, please visit https://youtu.be/9qfzzR9QB-I

 

EvoEnzyme collaboration

23/09/2019

EvoEnzyme as collaborator of SynCell participated on SynCell2019.

An event in which scientists from all over the world were discussing the different applications of artificial cells in health, food, renewable energy and biomaterials.

More info in

http://www.syntheticcell.eu/

EvoEnzyme in #WER19

04/03/2019
The Women in Entrepeneurship European Roadshow 2019 organized by the European Young Innovators Forum selected Maria Urbano, our CEO and Co-Founder to join this event. She was one of the 300 women, 30 VCs, 10 cities in 1 year.
(https://euwomenroadshow.eu/wer19-first-stop-in-madrid-was-an-absolute-success/)

EvoEnzyme, The most innovative technological initiative in Health

18/12/2018
Last December 2018, EvoEnzyme was awarded with the first prize of Madrid Health Start from Madri+D Foundation, which promotes the launch of the most promising start-ups biotech companies in the field of health in Spain. (http://www.madrimasd.org/healthstart/).

LATEST PUBLICATIONS

Mateljak, I., Rice, A., Yang, K., Tron, T. and Alcalde, M. (2019).

The generation of thermostable fungal laccase chimeras by SCHEMA-RASPP structure-guided recombination in vivo.

ACS Synthetic Biology 8: 833-843. JOURNAL COVER. (https://pubs.acs.org/doi/10.1021/acssynbio.8b00509).

Gomez de Santos, P., Cervantes, F.V., Tieves, F., Plou, F.J., Hollmann, F. and Alcalde, M. (2019).

Benchmarking of laboratory evolved unspecific peroxygenases for the synthesis of human drug metabolites.

Tetrahedron 75: 1827-1831. (https://doi.org/10.1016/j.tet.2019.02.013).

Viña‐Gonzalez J., Jimenez‐Lalana D., Sancho F., Serrano A., Martinez A., Guallar V. and Alcalde M. (2019).

Structure-guided evolution of aryl alcohol oxidase from Pleurotus eryngii for the selective oxidation of secondary benzyl alcohols.

Advanced Synthesis and Catalysis. 361: 2514-2525. (https://doi.org/10.1002/adsc.201900134).

Mateljak, I., Monza, E., Lucas, M.F., Guallar, V., Aleksejeva, O., Ludwig, R., Leech, D., Shleev, S. and Alcalde, M. (2019).

Increasing redox potential, redox mediator activity and stability in a fungal laccase by computer-guided mutagenesis and directed evolution.

ACS Catalysis 9: 4561-4572. (https://doi.org/10.1021/acscatal.9b00531).

*For a full list of publications, see www.miguelalcaldelab.eu